➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
AstraZeneca
Baxter
Merck
McKesson
Mallinckrodt

Last Updated: May 11, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CYCLOSERINE

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Cycloserine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000194 Neurobiology of Opioid Dependence: 3 - 3 Withdrawn National Institute on Drug Abuse (NIDA) Phase 2 1993-01-01 The purpose of this study is to study the effects of cycloserine on naloxone-precipitated opiate withdrawal.
NCT00000194 Neurobiology of Opioid Dependence: 3 - 3 Withdrawn Yale University Phase 2 1993-01-01 The purpose of this study is to study the effects of cycloserine on naloxone-precipitated opiate withdrawal.
NCT00000371 Trial of D-Cycloserine in Schizophrenia Completed Massachusetts General Hospital Phase 3 1996-08-01 To characterize further the effects of D-cycloserine augmentation of antipsychotic treatment on negative symptoms, performance on neurocognitive tasks, and on markers for glutamatergic, dopaminergic and serotonergic function in serum and cerebrospinal fluid. To determine if negative symptoms and cognitive function improve over time, if these improvements meaningfully impact quality of life factors, if they correlate with markers of neuronal function, and if subpopulations can be identified according to response. Dysfunction of glutamatergic neuronal systems has recently been implicated in the pathophysiology of schizophrenia based on the finding that non-competitive inhibitors of the NMDA receptor can reproduce in normals the positive symptoms, negative symptoms, and cognitive deficits of schizophrenia. Furthermore, glutamatergic dysfunction may alter forebrain dopaminergic neuronal activity, a system central to the antipsychotic action of typical neuroleptics. It is believed that enhancing NMDA receptor function by systemic treatment with D-cycloserine, a partial agonist at the glycine modulatory site of the NMDA receptor, will reduce symptoms in schizophrenia. Sixty schizophrenic outpatients with prominent, primary negative symptoms are treated with antipsychotic medication and are randomly assigned to D-cycloserine or placebo for a 6-month, fixed-dose trial. The primary outcome measure is the total score on the Scale for Assessment of Negative Symptoms (SANS). A neuropsychological battery, which emphasizes tests sensitive to prefrontal cortical function, is administered. Blood is obtained at several time points and CSF is obtained at Week 8 for assay of concentrations of D-cycloserine, glutamate, HVA, and 5HIAA.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Cycloserine

Condition Name

Condition Name for Cycloserine
Intervention Trials
Schizophrenia 12
Obsessive-compulsive Disorder 8
Major Depressive Disorder 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Cycloserine
Intervention Trials
Disease 19
Depression 12
Schizophrenia 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Cycloserine

Trials by Country

Trials by Country for Cycloserine
Location Trials
United States 100
China 32
Canada 6
Germany 5
Israel 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Cycloserine
Location Trials
Massachusetts 23
New York 14
Connecticut 8
Maryland 7
Illinois 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Cycloserine

Clinical Trial Phase

Clinical Trial Phase for Cycloserine
Clinical Trial Phase Trials
Phase 4 13
Phase 3 16
Phase 2/Phase 3 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Cycloserine
Clinical Trial Phase Trials
Completed 51
Recruiting 28
Unknown status 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Cycloserine

Sponsor Name

Sponsor Name for Cycloserine
Sponsor Trials
National Institute of Mental Health (NIMH) 15
Massachusetts General Hospital 15
Boston University 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Cycloserine
Sponsor Trials
Other 162
NIH 29
U.S. Fed 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Express Scripts
McKinsey
Colorcon
McKesson
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.